JAK1 inhibitor
Abrocitinib
Brand names: Cibinqo
Adult dose
Dose: 100 mg or 200 mg
Route: Oral
Frequency: Once daily
Clinical pearls
- Moderate–severe atopic dermatitis ≥12 y inadequately controlled
- MHRA JAKi class warnings on MACE/VTE/malignancy in >65/smokers
Contraindications
- Active serious infection/TB
- Severe hepatic impairment
- Pregnancy
Side effects
- Nausea
- Acne
- Herpes zoster
- VTE
- Cytopenias
Interactions
- Strong CYP2C19 inhibitors
- P-gp substrates
- Live vaccines
Monitoring
- FBC, LFTs, lipids
- TB/zoster screen
Reference: BNF; NICE TA814; MHRA DSU Sept 2023; SmPC Cibinqo. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD